U.S. Pharma Stock News

Wondering if Paychex at around US$92.55 is starting to look interesting again, or if the stock still has more to prove before it looks attractively priced. The share price is around US$92.55, with returns of around 0.1% over the past week, 1.8% over the past month, and a 14.8% decline year to date, while the 1 year return sits at a 33.0% decline. These moves sit against a longer backdrop where the stock has returned a 6.1% gain over 5 years, with a 6.5% decline over 3 years. This highlights...

Micron Technology (MU) has put up a big quarter, with Q2 2026 revenue of about US$23.9b, basic EPS of US$12.24 and net income of roughly US$13.8b. These figures feed into trailing 12 month EPS of US$21.49 on revenue of about US$58.1b and net income of roughly US$24.1b, alongside very large year over year earnings growth. The company has seen quarterly revenue move from US$8.1b and EPS of US$1.42 in Q2 2025 to US$23.9b and EPS of US$12.24 in Q2 2026. Over the same period, trailing net profit...

Ormat Technologies (NYSE:ORA) has priced $875 million of convertible senior notes in a significantly upsized offering. The company plans to use the proceeds to repurchase existing debt and shares, reshaping its capital structure. The transaction introduces new convertible securities that can affect future dilution and interest costs for shareholders. For readers tracking NYSE:ORA, this financing move comes with the stock at $110.52 and a 1 year return of 54.2%. Over 3 and 5 years, returns...

Edwards Lifesciences (NYSE:EW) has appointed Niranjan Pai as Director, Government Affairs. The new appointment places an experienced policy professional in a role focused on public policy and regulatory engagement. For investors tracking Edwards Lifesciences at a share price of $82.46, this move adds another piece to the broader picture around NYSE:EW. The company’s 1 year return of 16.2% sits alongside more modest 3 year and 5 year returns of 3.7% and 2.4%, which may prompt readers to pay...

Village Farms International reported fourth-quarter 2025 sales of US$49.62 million and net income of US$2.43 million, alongside full-year 2025 sales of US$215.94 million and net income of US$32.44 million, marking a shift from losses a year earlier. Over the same period, the company completed a repurchase of 812,923 shares for US$2.98 million, which, combined with the earnings turnaround, highlights management’s emphasis on improving profitability while also returning capital to...

ESAB Corporation (NYSE:ESAB) has priced a US$1b senior notes offering to fund the acquisition of Eddyfi Holding Inc. The deal is structured as a debt financed transaction, with the notes backed by guarantees from ESAB subsidiaries. This move follows a period of slower organic sales growth and reflects management’s focus on acquisitions to support expansion. ESAB, known for welding, cutting and gas control equipment, is moving to add Eddyfi’s testing and inspection capabilities to its...

W.W. Grainger (NYSE:GWW) has been named one of the 2026 World's Most Ethical Companies by Ethisphere. This is Grainger's second consecutive year receiving the recognition. The award highlights the company's focus on corporate governance, ethics, and responsible business practices. For investors following NYSE:GWW, this recognition comes on top of its role as a major distributor of maintenance, repair, and operating products to businesses and institutions. Ethical credentials can be...

Event context and recent share performance TEGNA (TGNA) shares recently closed at US$20.03, with the stock showing a roughly 1.3% decline over the past day, a 0.9% decline over the past week, and a 4.1% decline over the past month. See our latest analysis for TEGNA. While the recent 1 month share price return of a 4.1% decline has cooled momentum, the 1 year total shareholder return of 9.5% and 3 year total shareholder return of 39.5% point to a stronger longer term record. If you are...

If you are wondering whether NNN REIT is fairly priced or offering value at today's levels, this article walks through what the current market price might be implying. The stock recently closed at US$44.23, with returns of 11.9% year to date and 12.6% over the last year, plus 27.2% over 3 years and 30.5% over 5 years. These figures may have changed how the market views its risk and reward profile. Recent attention on NNN REIT has focused on its role as a retail focused REIT and how its...

The National Association of Insurance Commissioners is reviewing rated note feeder structures used by Carlyle Group (NasdaqGS:CG) and other private equity firms to channel insurance capital into higher risk assets. Potential changes under discussion focus on how these vehicles are reported and how much capital insurers must hold against them. The outcome of this review could affect the flow of insurance money into private credit and alternative investments managed by Carlyle. Carlyle Group...

Alibaba Group Holding (BABA) Q3 2026 earnings snapshot Alibaba Group Holding (BABA) just posted Q3 2026 results with revenue of ¥284.8b and basic EPS of ¥7.03, as investors weigh these numbers against a forecast calling for revenue growth of 9.1% per year and earnings growth of about 19.6% per year. The company has seen quarterly revenue move between ¥236.5b and ¥284.8b over the past six reported periods, while basic EPS has ranged from ¥5.36 to ¥21.07, set against trailing twelve month EPS...

Wondering whether SkyWest's current share price reflects its true value, or if the market is mispricing the stock. SkyWest recently closed at US$89.36, with a 0.2% decline over 7 days, a 16.8% decline over 30 days, an 11.7% decline year to date, a 1.1% decline over 1 year, a very large gain over 3 years and a 66.0% gain over 5 years, which may have caught your attention. Recent price moves sit against a backdrop where investors are reassessing airlines and regional carriers in light of...

If you are wondering whether York Space Systems at around US$17.68 offers value or just extra risk, the key is to separate short term noise from what the current price actually implies. The share price has recently been under pressure, with a 7 day return of 11.5% decline, a 30 day move of 36.9% decline, and a year to date return of 47.4% decline. This naturally raises questions about whether sentiment has swung too far. Recent news coverage has focused on York Space Systems as part of the...

The conflict in Iran that is limiting fertilizer shipments through the Strait of Hormuz has pushed nitrogen producers into focus, with CVR Partners (UAN) drawing attention as supply tightens and ammonia prices respond. See our latest analysis for CVR Partners. At a share price of $131.26, CVR Partners has seen a 30 day share price return of 22.67% and a 90 day share price return of 37.47%, while the 1 year total shareholder return of 93.50% reflects strong long term gains. This suggests that...

CytomX Therapeutics recently reported full-year 2025 results showing sales of US$76.2 million and a net loss of US$17.37 million, and has just raised roughly US$250.00 million through a follow-on offering of common stock and pre-funded warrants at about US$5.30 per security. At the same time, the company released encouraging Phase 1 data for its EpCAM-targeted ADC Varseta-M in heavily pretreated metastatic colorectal cancer, with a high disease control rate and a safety profile that appears...

Titan America (NYSE:TTAM) has agreed to acquire Keystone Cement, expanding its presence and capacity in the Mid-Atlantic region. The company reports record revenue, EBITDA and operating cash flows for 2025, despite sector headwinds. These developments have not yet been widely discussed and may reshape Titan America's growth profile and operational footprint. For investors tracking NYSE:TTAM, the stock last closed at $14.71, with a 1 year return of 15.1% and a 12.0% decline year to date...

Why Protalix BioTherapeutics is Back on Investors’ Radar Protalix BioTherapeutics (PLX) has drawn fresh attention after the European Commission approved a new Elfabrio dosing regimen for certain Fabry disease patients, alongside updated 2026 revenue guidance that includes a US$25 million regulatory milestone. See our latest analysis for Protalix BioTherapeutics. The Elfabrio dosing news and 2026 guidance update arrive after a mixed share price pattern, with a 28.9% 90 day share price return...

For investors considering whether Vornado Realty Trust at around US$26.48 reflects enough potential or already embeds too much optimism, this article breaks down what the current share price really represents. The stock has had a mixed run, with a 1.7% gain over the last 7 days, an 8.8% decline over the last 30 days, a 20.8% decline year to date, a 29.9% decline over 1 year, and a 114.6% return over 3 years, compared with a 32.1% decline over 5 years. Recent coverage around Vornado Realty...

Wondering whether THOR Industries at around US$76 a share is a bargain or a value trap? This article walks through the numbers so you can judge whether the current price lines up with the fundamentals. The stock has seen a 7.3% decline over the past week, a 33.5% decline over the past month, and is down 27.6% year to date, while the 1-year return sits at a 2.7% decline. These moves have kept THOR Industries on many watchlists, with investors reacting to ongoing headlines around the broader...

Ovid Therapeutics (OVID) has drawn fresh attention after reporting Phase 1 data for its OV329 epilepsy program at a 7 mg dose, alongside plans to expand into new seizure indications backed by about US$60 million in private financing. See our latest analysis for Ovid Therapeutics. The new OV329 data and US$60 million financing arrive after a sharp run in the stock, with a 30 day share price return of 60.84% and a 1 year total shareholder return above 400%, even though the 3 year and 5 year...

Collegium Pharmaceutical (NasdaqGS:COLL) has entered into a definitive agreement to acquire AZSTARYS. The deal expands Collegium’s ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings. The transaction is described as immediately accretive to adjusted EBITDA. For investors following the ADHD treatment space, this move provides another data point on how branded therapies are being repositioned. Collegium, which focuses on pain and ADHD treatments, is adding...

If you are wondering whether NBT Bancorp at around US$40.97 is starting to look interesting, the current share price and fundamentals raise some clear valuation questions worth unpacking. The stock has seen a 0.7% decline over the last week, a 10.4% decline over the past month, and a 1.5% decline year to date, while the 1 year, 3 year, and 5 year returns stand at a 1.9% decline, 34.7%, and 21.3% respectively. Recent attention on regional banks, regulatory capital expectations, and investor...

Firefly Aerospace (NasdaqGM:FLY) completed its first commercial moon landing in 2025, expanding its activity beyond Earth orbit missions. The company listed its shares in a high profile IPO in 2025, providing wider access to capital markets. Firefly reported major revenue growth in 2025 and acquired SciTec to deepen its national security and defense related offerings. For investors tracking Firefly Aerospace at a current share price of $22.96, 2025 marked a shift in scale and scope. The...

Globant (NYSE:GLOB) announced an AI focused collaboration with PharmaMar to support cancer drug discovery efforts. The company also agreed a global integration partnership with payments platform Adyen for enterprise clients. Both arrangements position Globant in healthcare and fintech projects tied to drug research and digital payments infrastructure. Globant operates as a digital services and technology company, working with enterprises that are investing in cloud, data and AI based...